Switzerland: Management Lonza Aligns Business to Strengthen Pharma, Biotech and Nutrition Offerings
The company has combined its Pharma & Biotech as well as Consumer Health & Nutrition business to form a new Lonza Pharma Biotech & Nutrition (LPBN) segment. Stefan Stoffel has been appointed as the COO of this new segment.
Basel/Switzerland – Lonza has recently announced the internal alignment of its business structure to accelerate growth along the Healthcare Continuum and strengthen the Microbial Control business. Stefan Stoffel has been appointed to a new role on the Executive Committee as COO, Lonza Pharma Biotech & Nutrition (LPBN), responsible for operations, from March 1.
The company will maintain two segments spanning the Healthcare Continuum – one dedicated to Lonza Specialty Ingredients (LSI) that will retain Consumer & Resources Protection as well as Consumer Product Ingredients and a second to Lonza Pharma Biotech & Nutrition (LPBN), combining Pharma & Biotech and Consumer Health & Nutrition.
In his newly created position, Stefan Stoffel will cover Operations, Quality, Engineering and Strategic Growth Initiatives across the LPBN segment. Stefan has been with Lonza since 1991 and has been instrumental in setting up a number of successful strategic projects, including Ibex. Stefan will join Marc Funk (incoming CEO), Sven Abend (COO LSI) and Rodolfo Savitzky (CFO) on the Executive Committee. The commercial functions of the new LPBN segment will be driven by Marc Funk for the time being.
The alignment will enable both segments to focus on operational excellence, including an integrated global asset strategy that enables a more-cohesive supply chain and asset utilisation. For the LSI segment, synergies across R&D and commercial functions will open up new market opportunities for the Microbial Control business and enable faster innovation. In the LPBN segment, translation of technology and knowhow from pharma to nutrition, including regulatory and scientific expertise, will strengthen Lonza’s offering.
With this new structure, Lonza is positioned to leverage its innovation programmes and technology platforms to create new solutions at the food-pharma convergence and in microbial control. Along the full spectrum, from advanced personalised medicines to functional foods, nutrition and a healthy environment, Lonza will continue to focus on driving a differentiated offering to support healthy living and to fully serve the needs of patients and consumers.
All future financial reporting will be based on the two new segments Lonza Pharma Biotech & Nutrition (LPBN) and Lonza Specialty Ingredients (LSI).
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 45777079)